CORCEPT THERAPEUTICS INC Payments to Acquire Debt Securities, Available-for-sale
CORCEPT THERAPEUTICS INC (CORT) reported Payments to Acquire Debt Securities, Available-for-sale of $355.07 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-02-28
- CORCEPT THERAPEUTICS INC payments to acquire debt securities, available-for-sale for fiscal 2022 was $355.07M, a 13.51% increase from fiscal 2021.
- CORCEPT THERAPEUTICS INC payments to acquire debt securities, available-for-sale for fiscal 2021 was $312.81M, a 25.54% decline from fiscal 2020.
- CORCEPT THERAPEUTICS INC payments to acquire debt securities, available-for-sale for fiscal 2020 was $420.11M, a 40.49% increase from fiscal 2019.
- CORCEPT THERAPEUTICS INC payments to acquire debt securities, available-for-sale for fiscal 2019 was $299.04M, a 28.27% increase from fiscal 2018.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 158 month | Payments to Acquire Debt Securities, Available-for-sale 161 month | Payments to Acquire Debt Securities, Available-for-sale 164 month | Payments to Acquire Debt Securities, Available-for-sale 167 month |
|---|---|---|---|---|---|
| 2022-12-31 | $355.07M 10-K · filed 2023-02-28 | ||||
| 2021-12-31 | $312.81M 10-K · filed 2023-02-28 | ||||
| 2020-12-31 | $420.11M 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $299.04M 10-K · filed 2022-02-15 | ||||
| 2018-12-31 | $233.12M 10-K · filed 2021-02-23 | ||||
| 2017-12-31 | $102.99M 10-K · filed 2020-02-24 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 | ||||
| 2012-03-31 | $118.32M 10-Q · filed 2012-05-10 | ||||
| 2011-12-31 | $118.32M 10-K · filed 2012-03-13 | ||||
| 2011-09-30 | $118.32M 10-Q · filed 2011-11-08 | ||||
| 2011-06-30 | $118.32M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |